Skip to main content

Advertisement

SpringerLink
Log in

Why anti-Bcl-2 clinical trials fail: a solution

  • Clinical
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

The alteration in expression of B cell lymphoma-2 (Bcl-2) family of protein members in cancer is involved mainly in the regulation of apoptosis. Bcl-2 family proteins are currently used as major targets in the development of methods to improve treatment outcomes for cancer patients that underwent clinical trials. Although many agents have been developed for targeting Bcl-2 in the past decade, some previous attempts to target Bcl-2 have not resulted in beneficial clinical outcome for reasons unknown. Here, we propose that this was due in part for not considering the cellular level of a different antiapoptotic protein, i.e., galectin-3 (Gal-3). Gal-3 is a member of the β-galactoside binding protein family and a multifunctional oncogenic protein which regulates cell growth, cell adhesion, cell proliferation, angiogenesis, and apoptosis. Gal-3 is the sole protein that contains the NWGR anti-death motif of the Bcl-2 family and inhibits cell apoptosis induced by chemotherapeutic agents through phosphorylation, translocation and regulation of survival signaling pathways. It is now established that Gal-3 is a candidate target protein to suppress antiapoptotic activity and anticancer drug resistance. In this review, we describe the role and relevance of Gal-3 and Bcl-2 protein family in the regulation of apoptosis and propose a novel combination therapy modality. Combination therapy that targets Gal-3 could be essential for improvement of the efficacy of Bcl-2 targeting therapy in cancers and should be studied in future clinical trials. Otherwise, not considering Gal-3 cellular level could lead to trial failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Danial, N. N., & Korsmeyer, S. J. (2004). Cell death: critical control points. Cell, 116, 205–219.

    PubMed  CAS  Google Scholar 

  2. Cotter, T. G. (2009). Apoptosis and cancer: the genesis of a research field. Nature reviews. Cancer, 9, 501–507.

    PubMed  CAS  Google Scholar 

  3. Green, D. R., & Reed, J. C. (1998). Mitochondria and apoptosis. Science, 281, 1309–1312.

    PubMed  CAS  Google Scholar 

  4. Haldar, S., Basu, A., & Croce, C. M. (1998). Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Research, 58, 1609–1615.

    PubMed  CAS  Google Scholar 

  5. Ito, T., Deng, X., Carr, B., & May, W. S. (1997). Bcl-2 phosphorylation required for anti-apoptosis function. The Journal of Biological Chemistry, 272, 11671–11673.

    PubMed  CAS  Google Scholar 

  6. Ojala, P. M., Yamamoto, K., Castanos-Velez, E., Biberfeld, P., Korsmeyer, S. J., & Makela, T. P. (2000). The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nature Cell Biology, 2, 819–825.

    PubMed  CAS  Google Scholar 

  7. Pratesi, G., Perego, P., & Zunino, F. (2001). Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochemical Pharmacology, 61, 381–386.

    PubMed  CAS  Google Scholar 

  8. Ruvolo, P. P., Deng, X., Carr, B. K., & May, W. S. (1998). A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. The Journal of Biological Chemistry, 273, 25436–25442.

    PubMed  CAS  Google Scholar 

  9. Salah-Eldin, A. E., Inoue, S., Tsukamoto, S., Aoi, H., & Tsuda, M. (2003). An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. International journal of cancer. Journal International du Cancer, 103, 53–60.

    PubMed  CAS  Google Scholar 

  10. Yamamoto, K., Ichijo, H., & Korsmeyer, S. J. (1999). BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Molecular and Cellular Biology, 19, 8469–8478.

    PubMed Central  PubMed  CAS  Google Scholar 

  11. Yokote, H., Terada, T., Matsumoto, H., Kakishita, K., Kinoshita, Y., Nakao, N., et al. (2000). Dephosphorylation-induced decrease of anti-apoptotic function of Bcl-2 in neuronally differentiated P19 cells following ischemic insults. Brain Research, 857, 78–86.

    PubMed  CAS  Google Scholar 

  12. Leber, B., Geng, F., Kale, J., & Andrews, D. W. (2010). Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Reviews in Molecular Medicine, 12, e28.

    PubMed  Google Scholar 

  13. Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., et al. (2012). Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 488–496.

    CAS  Google Scholar 

  14. Barondes, S. H., Cooper, D. N., Gitt, M. A., & Leffler, H. (1994). Galectins. Structure and function of a large family of animal lectins. The Journal of Biological Chemistry, 269, 20807–20810.

    PubMed  CAS  Google Scholar 

  15. Ochieng, J., Fridman, R., Nangia-Makker, P., Kleiner, D. E., Liotta, L. A., Stetler-Stevenson, W. G., et al. (1994). Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry, 33, 14109–14114.

    PubMed  CAS  Google Scholar 

  16. Liu, F. T., Hsu, D. K., Zuberi, R. I., Kuwabara, I., Chi, E. Y., & Henderson, W. R., Jr. (1995). Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. The American Journal of Pathology, 147, 1016–1028.

    PubMed Central  PubMed  CAS  Google Scholar 

  17. Xu, X. C., el-Naggar, A. K., & Lotan, R. (1995). Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. The American journal of Pathology, 147, 815–822.

    PubMed Central  PubMed  CAS  Google Scholar 

  18. Hsu, D. K., Hammes, S. R., Kuwabara, I., Greene, W. C., & Liu, F. T. (1996). Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. The American Journal of Pathology, 148, 1661–1670.

    PubMed Central  PubMed  CAS  Google Scholar 

  19. Konstantinov, K. N., Robbins, B. A., & Liu, F. T. (1996). Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. The American Journal of Pathology, 148, 25–30.

    PubMed Central  PubMed  CAS  Google Scholar 

  20. van den Brule, F. A., Buicu, C., Berchuck, A., Bast, R. C., Deprez, M., Liu, F. T., et al. (1996). Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Human Pathology, 27, 1185–1191.

    PubMed  Google Scholar 

  21. Lotan, R., Ito, H., Yasui, W., Yokozaki, H., Lotan, D., & Tahara, E. (1994). Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. International journal of cancer. Journal International du Cancer, 56, 474–480.

    PubMed  CAS  Google Scholar 

  22. Schoeppner, H. L., Raz, A., Ho, S. B., & Bresalier, R. S. (1995). Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer, 75, 2818–2826.

    PubMed  CAS  Google Scholar 

  23. Barondes, S. H., Castronovo, V., Cooper, D. N., Cummings, R. D., Drickamer, K., Feizi, T., et al. (1994). Galectins: a family of animal beta-galactoside-binding lectins. Cell, 76, 597–598.

    PubMed  CAS  Google Scholar 

  24. Perillo, N. L., Marcus, M. E., & Baum, L. G. (1998). Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. Journal of Molecular Medicine, 76, 402–412.

    PubMed  CAS  Google Scholar 

  25. Inohara, H., Akahani, S., & Raz, A. (1998). Galectin-3 stimulates cell proliferation. Experimental Cell Research, 245, 294–302.

    PubMed  CAS  Google Scholar 

  26. Inohara, H., & Raz, A. (1995). Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Research, 55, 3267–3271.

    PubMed  CAS  Google Scholar 

  27. Nangia-Makker, P., Honjo, Y., Sarvis, R., Akahani, S., Hogan, V., Pienta, K. J., et al. (2000). Galectin-3 induces endothelial cell morphogenesis and angiogenesis. The American journal of Pathology, 156, 899–909.

    PubMed Central  PubMed  CAS  Google Scholar 

  28. Yang, R. Y., & Liu, F. T. (2003). Galectins in cell growth and apoptosis. Cellular and Molecular Life Sciences: CMLS, 60, 267–276.

    PubMed  CAS  Google Scholar 

  29. Fukumori, T., Takenaka, Y., Oka, N., Yoshii, T., Hogan, V., Inohara, H., et al. (2004). Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Research, 64, 3376–3379.

    PubMed  CAS  Google Scholar 

  30. Nangia-Makker, P., Nakahara, S., Hogan, V., & Raz, A. (2007). Galectin-3 in apoptosis, a novel therapeutic target. Journal of Bioenergetics and Biomembranes, 39, 79–84.

    PubMed Central  PubMed  CAS  Google Scholar 

  31. Akahani, S., Nangia-Makker, P., Inohara, H., Kim, H. R., & Raz, A. (1997). Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Research, 57, 5272–5276.

    PubMed  CAS  Google Scholar 

  32. Kim, H. R., Lin, H. M., Biliran, H., & Raz, A. (1999). Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Research, 59, 4148–4154.

    PubMed  CAS  Google Scholar 

  33. Lin, H. M., Moon, B. K., Yu, F., & Kim, H. R. (2000). Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis, 21, 1941–1945.

    PubMed  CAS  Google Scholar 

  34. Yoshii, T., Fukumori, T., Honjo, Y., Inohara, H., Kim, H. R., & Raz, A. (2002). Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. The Journal of Biological Chemistry, 277, 6852–6857.

    PubMed  Google Scholar 

  35. Fukumori, T., Oka, N., Takenaka, Y., Nangia-Makker, P., Elsamman, E., Kasai, T., et al. (2006). Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Research, 66, 3114–3119.

    PubMed  CAS  Google Scholar 

  36. Takenaka, Y., Fukumori, T., Yoshii, T., Oka, N., Inohara, H., Kim, H. R., et al. (2004). Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Molecular and Cellular Biology, 24, 4395–4406.

    PubMed Central  PubMed  CAS  Google Scholar 

  37. Nakahara, S., Hogan, V., Inohara, H., & Raz, A. (2006). Importin-mediated nuclear translocation of galectin-3. The Journal of Biological Chemistry, 281, 39649–39659.

    PubMed  CAS  Google Scholar 

  38. van den Brule, F. A., Waltregny, D., Liu, F. T., & Castronovo, V. (2000). Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. International journal of cancer. Journal International du Cancer, 89, 361–367.

    PubMed  Google Scholar 

  39. Yu, F., Finley, R. L., Jr., Raz, A., & Kim, H. R. (2002). Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. The Journal of Biological Chemistry, 277, 15819–15827.

    PubMed  CAS  Google Scholar 

  40. Reed, J. C., & Pellecchia, M. (2005). Apoptosis-based therapies for hematologic malignancies. Blood, 106, 408–418.

    PubMed  CAS  Google Scholar 

  41. Youle, R. J., & Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nature reviews. Molecular Cell Biology, 9, 47–59.

    PubMed  CAS  Google Scholar 

  42. Reed, J. C. (2008). Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood, 111, 3322–3330.

    PubMed Central  PubMed  CAS  Google Scholar 

  43. Weyhenmeyer, B., Murphy, A. C., Prehn, J. H., & Murphy, B. M. (2012). Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Experimental Oncology, 34, 192–199.

    PubMed  CAS  Google Scholar 

  44. Kang, M. H., & Reynolds, C. P. (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15, 1126–1132.

    CAS  Google Scholar 

  45. Wajant, H. (2002). The Fas signaling pathway: more than a paradigm. Science, 296, 1635–1636.

    PubMed  CAS  Google Scholar 

  46. Adams, J. M., & Cory, S. (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26, 1324–1337.

    PubMed Central  PubMed  CAS  Google Scholar 

  47. Kim, H., Rafiuddin-Shah, M., Tu, H. C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J., et al. (2006). Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nature Cell Biology, 8, 1348–1358.

    PubMed  CAS  Google Scholar 

  48. Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183–192.

    PubMed  CAS  Google Scholar 

  49. Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell, 17, 393–403.

    PubMed  CAS  Google Scholar 

  50. Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science, 315, 856–859.

    PubMed  CAS  Google Scholar 

  51. Leber, B., Lin, J., & Andrews, D. W. (2007). Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis: An International Journal on Programmed Cell Death, 12, 897–911.

    CAS  Google Scholar 

  52. Yin, X. M., Oltvai, Z. N., & Korsmeyer, S. J. (1994). BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature, 369, 321–323.

    PubMed  CAS  Google Scholar 

  53. Davids, M. S., & Letai, A. (2012). Targeting the B-cell lymphoma/leukemia 2 family in cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 3127–3135.

    CAS  Google Scholar 

  54. Klasa, R. J., Gillum, A. M., Klem, R. E., & Frankel, S. R. (2002). Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense & Nucleic Acid Drug Development, 12, 193–213.

    CAS  Google Scholar 

  55. Chi, K. N., Gleave, M. E., Klasa, R., Murray, N., Bryce, C., Lopes de Menezes, D. E., et al. (2001). A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7, 3920–3927.

    CAS  Google Scholar 

  56. Marcucci, G., Byrd, J. C., Dai, G., Klisovic, M. I., Kourlas, P. J., Young, D. C., et al. (2003). Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 101, 425–432.

    PubMed  CAS  Google Scholar 

  57. Tolcher, A. W., Kuhn, J., Schwartz, G., Patnaik, A., Hammond, L. A., Thompson, I., et al. (2004). A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 5048–5057.

    CAS  Google Scholar 

  58. Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., et al. (2006). Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24, 4738–4745.

    CAS  Google Scholar 

  59. O’Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A. B., Koziner, B., et al. (2009). 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 5208–5212.

    Google Scholar 

  60. Rudin, C. M., Salgia, R., Wang, X., Hodgson, L. D., Masters, G. A., Green, M., et al. (2008). Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 870–876.

    CAS  Google Scholar 

  61. Wei, J., Kitada, S., Rega, M. F., Emdadi, A., Yuan, H., Cellitti, J., et al. (2009). Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Molecular Cancer Therapeutics, 8, 904–913.

    PubMed Central  PubMed  CAS  Google Scholar 

  62. Mohammad, R. M., Wang, S., Aboukameel, A., Chen, B., Wu, X., Chen, J., et al. (2005). Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics, 4, 13–21.

    PubMed  CAS  Google Scholar 

  63. Shelley, M. D., Hartley, L., Groundwater, P. W., & Fish, R. G. (2000). Structure-activity studies on gossypol in tumor cell lines. Anti-Cancer Drugs, 11, 209–216.

    PubMed  CAS  Google Scholar 

  64. Vogler, M., Weber, K., Dinsdale, D., Schmitz, I., Schulze-Osthoff, K., Dyer, M. J., et al. (2009). Different forms of cell death induced by putative BCL2 inhibitors. Cell Death and Differentiation, 16, 1030–1039.

    PubMed  CAS  Google Scholar 

  65. Shore, G. C., & Viallet, J. (2005). Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 226–230.

  66. Zhai, D., Jin, C., Satterthwait, A. C., & Reed, J. C. (2006). Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death And Differentiation, 13, 1419–1421.

    PubMed  CAS  Google Scholar 

  67. O’Brien, S. M., Claxton, D. F., Crump, M., Faderl, S., Kipps, T., Keating, M. J., et al. (2009). Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood, 113, 299–305.

    PubMed  Google Scholar 

  68. Schimmer, A. D., O’Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., et al. (2008). A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14, 8295–8301.

    CAS  Google Scholar 

  69. Oki, Y., Copeland, A., Hagemeister, F., Fayad, L. E., Fanale, M., Romaguera, J., et al. (2012). Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood, 119, 2171–2172.

    PubMed  CAS  Google Scholar 

  70. Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A., Rizvi, N. A., Takebe, N., et al. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer, 74, 481–485.

    PubMed Central  PubMed  Google Scholar 

  71. Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., & Stewart, A. K. (2007). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 109, 5430–5438.

    PubMed  CAS  Google Scholar 

  72. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677–681.

    PubMed  CAS  Google Scholar 

  73. Kang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T. M., et al. (2007). Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood, 110, 2057–2066.

    PubMed  CAS  Google Scholar 

  74. Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., et al. (2006). Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 10, 375–388.

    PubMed  CAS  Google Scholar 

  75. van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., et al. (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 10, 389–399.

    PubMed Central  PubMed  Google Scholar 

  76. Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research, 68, 3421–3428.

    PubMed  CAS  Google Scholar 

  77. Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., et al. (2011). Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 909–916.

    CAS  Google Scholar 

  78. Wilson, W. H., O’Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., et al. (2010). Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The lancet Oncology, 11, 1149–1159.

    PubMed Central  PubMed  CAS  Google Scholar 

  79. Rudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., et al. (2012). Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 18, 3163–3169.

    CAS  Google Scholar 

  80. Mazumder, S., Choudhary, G. S., Al-Harbi, S., & Almasan, A. (2012). Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Research, 72, 3069–3079.

    PubMed Central  PubMed  CAS  Google Scholar 

  81. Xu, H., & Krystal, G. W. (2010). Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16, 4392–4400.

    CAS  Google Scholar 

  82. Zhang, C., Cai, T. Y., Zhu, H., Yang, L. Q., Jiang, H., Dong, X. W., et al. (2011). Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Molecular Cancer Therapeutics, 10, 1264–1275.

    PubMed  CAS  Google Scholar 

  83. Yang, R. Y., Rabinovich, G. A., & Liu, F. T. (2008). Galectins: structure, function and therapeutic potential. Expert Reviews in Molecular Medicine, 10, e17.

    PubMed  Google Scholar 

  84. Prieto, V. G., Mourad-Zeidan, A. A., Melnikova, V., Johnson, M. M., Lopez, A., Diwan, A. H., et al. (2006). Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12, 6709–6715.

    CAS  Google Scholar 

  85. Kopper, L., & Timar, J. (2006). Genomics of renal cell cancer—does it provide breakthrough? Pathology Oncology Research: POR, 12, 5–11.

    PubMed  CAS  Google Scholar 

  86. Califice, S., Castronovo, V., & Van Den Brule, F. (2004). Galectin-3 and cancer (Review). International Journal of Oncology, 25, 983–992.

    PubMed  CAS  Google Scholar 

  87. Fukumori, T., Kanayama, H. O., & Raz, A. (2007). The role of galectin-3 in cancer drug resistance. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 10, 101–108.

    CAS  Google Scholar 

  88. Huflejt, M. E., Turck, C. W., Lindstedt, R., Barondes, S. H., & Leffler, H. (1993). L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. The Journal of Biological Chemistry, 268, 26712–26718.

    PubMed  CAS  Google Scholar 

  89. Mazurek, N., Conklin, J., Byrd, J. C., Raz, A., & Bresalier, R. S. (2000). Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. The Journal of Biological Chemistry, 275, 36311–36315.

    PubMed  CAS  Google Scholar 

  90. Matarrese, P., Fusco, O., Tinari, N., Natoli, C., Liu, F. T., Semeraro, M. L., et al. (2000). Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. International journal of cancer. Journal International du Cancer, 85, 545–554.

    PubMed  CAS  Google Scholar 

  91. Yang, R. Y., Hsu, D. K., & Liu, F. T. (1996). Expression of galectin-3 modulates T-cell growth and apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 93, 6737–6742.

    PubMed Central  PubMed  CAS  Google Scholar 

  92. Nakahara, S., Oka, N., Wang, Y., Hogan, V., Inohara, H., & Raz, A. (2006). Characterization of the nuclear import pathways of galectin-3. Cancer Research, 66, 9995–10006.

    PubMed  CAS  Google Scholar 

  93. Oka, N., Nakahara, S., Takenaka, Y., Fukumori, T., Hogan, V., Kanayama, H. O., et al. (2005). Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Research, 65, 7546–7553.

    PubMed  CAS  Google Scholar 

  94. Pieters, R. J. (2006). Inhibition and detection of galectins. Chembiochem: A European journal of Chemical Biology, 7, 721–728.

    CAS  Google Scholar 

  95. Delaine, T., Cumpstey, I., Ingrassia, L., Le Mercier, M., Okechukwu, P., Leffler, H., et al. (2008). Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. Journal of Medicinal Chemistry, 51, 8109–8114.

    PubMed  CAS  Google Scholar 

  96. Lin, C. I., Whang, E. E., Donner, D. B., Jiang, X., Price, B. D., Carothers, A. M., et al. (2009). Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Molecular Cancer Research: MCR, 7, 1655–1662.

    PubMed  CAS  Google Scholar 

  97. Inohara, H., & Raz, A. (1994). Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconjugate Journal, 11, 527–532.

    PubMed  CAS  Google Scholar 

  98. Nangia-Makker, P., Hogan, V., Honjo, Y., Baccarini, S., Tait, L., Bresalier, R., et al. (2002). Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. Journal of the National Cancer Institute, 94, 1854–1862.

    PubMed  CAS  Google Scholar 

  99. Pienta, K. J., Naik, H., Akhtar, A., Yamazaki, K., Replogle, T. S., Lehr, J., et al. (1995). Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. Journal of the National Cancer Institute, 87, 348–353.

    PubMed  CAS  Google Scholar 

  100. Streetly, M. J., Maharaj, L., Joel, S., Schey, S. A., Gribben, J. G., & Cotter, F. E. (2010). GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood, 115, 3939–3948.

    PubMed  CAS  Google Scholar 

  101. Chauhan, D., Li, G., Podar, K., Hideshima, T., Neri, P., He, D., et al. (2005). A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Research, 65, 8350–8358.

    PubMed  CAS  Google Scholar 

  102. Hanada, M., Aime-Sempe, C., Sato, T., & Reed, J. C. (1995). Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. The Journal of Biological Chemistry, 270, 11962–11969.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by the National Institute of Health grant R37CA46120 (to A.R.).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA

    Y. Harazono, K. Nakajima & A. Raz

  2. Department of Pathology, School of Medicine, Wayne State University, Detroit, MI, USA

    Y. Harazono, K. Nakajima & A. Raz

  3. Karmanos Cancer Institute, Detroit, MI, 48201, USA

    Y. Harazono, K. Nakajima & A. Raz

Authors
  1. Y. Harazono
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Raz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Raz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harazono, Y., Nakajima, K. & Raz, A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev 33, 285–294 (2014). https://doi.org/10.1007/s10555-013-9450-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-013-9450-8

Keywords

Search

Navigation